Researchers find medical industry funded studies more likely to find new treatments cost effective

New drugs and technologies covered by insurance plans can be much more profitable than those not covered, which may lead to bias in CEAs funded by pharmaceutical or other medical industry firms.
The research team gleaned its data by analysing the results of more than 8,000 CEAs published between 1976 and March 2021. Nearly 30 per cent of these CEAs were sponsored by industry.

Offering a Pay-for-Performance Program to Oncology Practices Increases Prescriptions of Evidence-based Cancer Drugs

A pay-for performance program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care, Penn Medicine researchers report in a new study published online in the Journal of Clinical Oncology.

ISPOR Publishes 2020 Top 10 Health Economics and Outcomes Research (HEOR) Trends Report

ISPOR—the professional society for health economics and outcomes research (HEOR), announced the publication of its 2020 Top 10 HEOR Trends report. In the report, the Society has identified the top 10 HEOR trends that will shape the field and influence healthcare over 2020 and the near future.